Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

g.

DIAGNOSTICS

We believe that we have a clear development pathway for our immunoassay test to determine the 2-2 genotype of Hp and have validated the accuracy of a commercial kit, as presented at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland, on September 11, 2008. Our pre-IDE meeting with the U.S. Food and Drug Administration has been completed, and we are on track to submit a 510(k) application for marketing clearance of this kit in the fourth quarter of 2008. In preparation for marketing clearance, we are preparing to launch the test with a small, dedicated sales force in the U.S., initially focused on high prescribers in the Mid-Atlantic region. We are also preparing a CE mark submission to market the test through distributors in the EU.

Of particular significance, research first presented at the American Heart Association's (AHA) Scientific Sessions November, 2007 in Orlando, Florida, and subsequently published in Arteriosclerosis, Thrombosis and Vascular Biology 2008 Feb;28(2):341-7. Epub 2007 Nov. 21, demonstrated that in patients with Diabetes Mellitus (DM) who had the Haptoglobin 2-2 (Hp2-2) genotype, supplementation with Vitamin E therapy decreased cardiovascular events. We believe that this provides a compelling disease management opportunity for payers who can recommend the use of our test to determine the appropriate use of Vitamin E and the potential reduction of heart attacks resulting in considerable healthcare savings.

In addition to these commercial and scientific advances for the Hp test, we have made considerable progress in the development of a test for CML, another proprietary cardiovascular risk marker. Last year, researchers published reports that CML may predict outcomes in patients with heart failure. Our product candidate alagebrium has been shown to affect CML levels in animal models and the marker is being tracked in our alagebrium Phase 2 programs involving a targe
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/24/2014)... Md. , Nov. 24, 2014  Spherix ... development company committed to the fostering and monetization ... Spherix v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M ... Case No. 3:13-cv-03496-M, both in the United States ... Texas . On ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2
... (GFP) in their retina cells or other tissues can ... real time computer record of movement and gene expression. ... BMC Biotechnology , will allow detailed analyses of ... Tower led a team of researchers from the University ...
... Washington Life Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 ... Alliance (WAVA) and to support initial research into,three new ... the,grant is funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides ... , WAVA core ...
... Office has,issued Nutraceutix, Inc. a patent for BIO-tract. It ... the technology has been awarded based,on BIO-tract,s ability to ... their way to optimal release sites in the,intestinal tract. ... Nutraceutix comments: "Many years ago,we recognized the need for ...
Cached Biology Technology:Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Probiotic Delivery Technology Awarded Third International Patent 2
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... NEW YORK , Aug. 16, 2013   EyeLock Inc. , a ... of Roger An as Vice President of Global ... for research, analysis and strategic initiatives to further the embedded ... a heavy focus on Asia .   ...
... 2013) Primary results from a new clinical ... treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) ... islet cell function, compared to controls. Further analyses ... that demonstrated especially robust responses ("responders"), suggesting that ...
... body is a complicated system of blood vessels, nerves, organs, ... When all are working together, it,s a symphony of form ... Biologist Rejji Kuruvilla and her fellow researchers uncovered what happens ... along with graduate students Philip Borden and Jessica Houtz, both ...
Cached Biology News:EyeLock Appoints Roger An Vice President of Global Market Development 2EyeLock Appoints Roger An Vice President of Global Market Development 3ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3Sympathetic neurons 'cross talk' with pancreas cells during early development 2Sympathetic neurons 'cross talk' with pancreas cells during early development 3
... System with Gateway™ Technology is designed ... the polyhedrin promoter. The expression cassette ... (bacmid DNA) by site-specific transposition (Tn7) ... recombinant bacmid DNA is then used ...
...
... Immunogen: Synthetic peptide derived from the ... bovine Math-2. Specificity: Specific for ... Rat (positive controls: human U251 A172 ... and rat brain homogenates)Storage: Store at ...
... OneSTrEP Protein Interaction Kit provides an ... method to isolate intact protein complexes. ... optimization or multiple purification steps, this ... selective StrepTactin Superflow Column for fast ...
Biology Products: